Index of Published Canadian Adverse Reaction Newsletters

April 2012; 22(2)

• Minocycline: drug-induced lupus erythematosus and autoimmune hepatitis in adolescents
• Fentanyl and serotonin syndrome
• Summary of advisories

January 2012; 22(1)

• Second-generation antipsychotics and cardiometabolic adverse reactions in children and adolescents
• Prescription drugs and pediatric patients
• Canadian Paediatric Surveillance Program
• Adverse reaction reporting in children: update
• Adverse reaction reporting form
• Did you know? The Drug Safety and Effectiveness Network (DSEN) and pediatric projects
• Summary of advisories

October 2011; 21(4)

• Custom-Pak Ophthalmic Surgery Procedure Pack: contamination with foreign bodies and risk of related complications
• Case presentation: Dental/surgical rotary handpieces and patient burns
• CARN's 20th anniversary
• Did you know? Medical devices and incidents
• Summary of advisories

July 2011; 21(3)

• Proton pump inhibitors: hypomagnesemia accompanied by hypocalcemia and hypokalemia
• Adverse reaction and incident reporting -- 2010
• Case presentation: Floseal hemostatic matrix and suspected association with misinterpretation as recurrent malignant disease
• Risk communication information
• Summary of advisories

April 2011; 21(2)

• Fluticasone propionate and osteonecrosis
• Rosiglitazone-fenofibrate interaction: severe paradoxical decreased high-density lipoprotein cholesterol levels
• Varenicline and hyperglycemia in patients with diabetes
• Quinine sulfate and serious adverse reactions
• Summary of advisories

January 2011; 21(1)

• Clozapine and life-threatening gastrointestinal hypomotility
• Case presentation: Bio-Alcamid soft-tissue endoprosthesis and suspected association with late infection
• Natural health product identification in adverse reaction reports
• Summary of advisories

October 2010; 20(4)

• Statins and interstitial lung disease
• Potential interference of computed tomography(CT) scanning with electronic medical devices
• Case presentation: Red Bull Energy Drink and suspected association with seizure
• New consumer form for reporting adverse reactions
• Summary of advisories

July 2010; 20(3)

• Pregabalin (Lyrica): suicidal ideation and attempt
• Adverse incidents with injectable hyaluronic acid dermal fillers
• Oral iron supplements: skin reactions and other hypersensitivity reactions
• Summary of advisories

April 2010; 20(2)

• Leflunomide and peripheral neuropathy
• Adverse reaction and incident reporting - 2009
• Summary of advisories

January 2010; 20(1)

• Black cohosh products and liver toxicity: update
• Canada Vigilance Online Database
• Case presentation: Denture adhesive creams and neuropathy
• Summary of advisories

October 2009; 19(4)

• Intravenous immune globulin (IVIG): hemolytic reactions
• Antiviral medications and influenza A (H1N1): reporting adverse reactions
• Sildenafil (Revatio): medication incident
• Adverse reaction reporting form
• Summary of advisories

July 2009; 19(3)

• Montelukast (Singulair): psychiatric reactions
• Intravitreal injection of triamcinolone acetonide: ocular reactions
• Fentanyl transdermal patches and accidental child exposure
• Summary of advisories

April 2009; 19(2)

• Atypical antipsychotics and agranulocytosis
• Adverse reaction and incident reporting - 2008
• Announcement: Cough and cold products
• Case presentation: 5-Hour Energy drink and a cardiovascular adverse reaction
• Adverse reaction reporting form
• Summary of advisories

January 2009; 19(1)

• Local anesthetic infusion with pain pumps and chondrolysis
• Natural health products and adverse reactions: update
• Case presentation: Propolis and renal failure
• Summary of advisories

October 2008; 18(4)

• Botulinum toxin type A and distant toxin spread
• Case presentation: IVIG and transfusion-related acute lung injury
• Cesium chloride and ventricular arrhythmias
• Summary of advisories

July 2008; 18(3)

• Fentanyl transdermal patch and fatal adverse reactions
• Atomoxetine and suicidal behaviour: update
• Twinject auto-injector and device malfunctions
• Summary of advisories

April 2008; 18(2)

• Varenicline and serious psychiatric reactions
• Serious adverse reaction and medication incident
• Adverse reaction reporting - 2007
• Summary of advisories

January 2008; 18(1)

• IVIG: myocardial infarction and cerebrovascular and thrombotic adverse reactions
• Case presentation: NuvaRing and aortic thrombosis
• Canada Vigilance Program
• Evra: myocardial infarction and thromboembolic adverse reactions
• Summary of advisories

October 2007; 17(4)

• Gadolinium-containing agents: update on nephrogenic systemic fibrosis
• Sibutramine and cardiovascular adverse reactions
• Swedish Adjustable Gastric Band and erosion
• Summary of advisories

July 2007; 17(3)

• Benadryl Total: medication incident and stroke
• Rosiglitazone and parotid gland enlargement: update
• Adverse reaction reporting: education modules
• Case presentation: Norethindrone and decreased breast milk production
• Summary of advisories

April 2007; 17(2)

• Quetiapine: pancreatitis and thrombocytopenia
• Case presentation: Telithromycin and toxic epidermal necrolysis
• Bitter orange (synephrine): update on cardiovascular reactions
• Adverse reaction reporting - 2006
• Summary of advisories

January 2007; 17(1)

• Levofloxacin: dysglycemia and liver disorders
• Domperidone: heart rate and rhythm disorders
• Case presentation: Green tea extract and hepatotoxicity
• Summary of advisories

July 2006; 16(3)

• Adverse reactions in children: Why report?
• Case presentations:
• Extended-release methylphenidate withdrawal: priapism
• Iodoquinol: hypertensive encephalopathy and seizures
• Symposium on drug, food and natural health product interactions
• Summary of advisories

April 2006; 16(2)

• Tenofovir and NSAIDs: acute renal failure
• Adverse reaction reporting - 2005
• Isotretinoin: myocardial infarction, cerebrovascular and thromboembolic disorders
• Case presentation: Overnight orthokeratology and Acanthamoeba keratitis
• Regional Adverse Reaction Centres: relocation
• Summary of advisories
  

January 2006; 16(1)

• Oseltamivir and warfarin: increase in INR
• Levonorgestrel-releasing intrauterine system and uterine perforation
• Guidance document for industry
• Energy drinks
• Case presentation: Rosiglitazone: parotid gland enlargement
• Summary of advisories
  

October 2005; 15(4)

• Intrathecal baclofen: pump system incidents
• Statins and memory loss
• Chloral hydrate and potassium chloride: medication incident
• Case presentation: Ayurvedic medicines: lead contamination
• New MedEffect e-notice and Web site
• Summary of advisories

July 2005; 15(3)

• Transdermal fentanyl: abuse in adolescents
• Black cohosh: international reports of liver toxicity
• Rosiglitazone: decreased HDL cholesterol levels
• Ibuprofen: Stevens-Johnson syndrome
• New Regional Adverse Reaction Centres
• Case presentation: mefloquine with QT prolongation
• Summary of advisories

April 2005; 15(2)

• Hylan G-F 20 : joint inflammation and pain
• Adverse reaction reporting - 2004
• Products derived from bees: serious adverse reactions
• Case presentation : rhabdomyolysis with clopidogrel, atorvastatin and cyclosporine
• Summary of advisories

January 2005; 15(1)

• Telithromycin and warfarin
• Linezolid and neuropathy
• Camphor and eucalyptus oils
• Adverse reaction reporting
• Natural weight loss product and myopathy
• Ceftriaxone and immune hemolytic anemia in children
• Case presentation : olanzapine and pulmonary embolism
• Summary of advisories

October 2004; 14(4)

• Transdermal fentanyl (Duragesic): respiratory arrest in adolescents
• Infliximab (Remicade) and etanercept (Enbrel): serious infections and tuberculosis
• Bitter orange (synephrine): cardiovascular reactions
• Case presentations:
  • Ibutilide and torsades de pointes
  • Tubersol and anaphylaxis
• Summary of advisories

July 2004; 14(3)

• Fluoroquinolones and warfarin: suspected interactions
• Suspected warfarin-cranberry juice interaction
• Case presentations:
  • Tutoplast Dura graft and Creutzfeldt-Jakob disease
  • Toxic shock syndrome and tampons
• Summary of advisories

April 2004; 14(2)

• Sterol and sterolin-containing products: hematologic adverse reactions
• Adverse reaction reporting - 2003
• Feasibility study of active surveillance of adverse reactions in children
• Public opinion survey on post-market surveillance
• Case presentation: clopidogrel
• Summary of advisories

January 2004; 14(1)

• Valdecoxib (Bextra^TM): severe cutaneous reactions
• Natural health products
• Case presentations:
  • Ciprofloxacin
  • Finasteride
• Drug Safety Information Workshop II Report
• Human growth hormone (somatropin): Prader-Willi syndrome
• Summary of advisories

October 2003; 13(4)

• Bisphosphonates and ocular disorders
• Fluticasone and adrenal suppression
• Adhesion prevention solutions in gynecological procedures
• Case presentation: intravenous immunoglobulins
• Summary of Advisories
• Insulin products

July 2003; 13(3)

• Gatifloxacin (Tequin^TM ): hypoglycemia and hyperglycemia
• Serotonin syndrome
• Summary of advisories
• Case presentation: red yeast rice and rhabdomyolysis

April 2003; 13(2)

• Withdrawal reactions with paroxetine and other SSRIs
• Adverse reaction reporting - 2002
• Case presentation: divalproex
• Safe use of products containing acetaminophen
• Hormone replacement therapy
• Summary of advisories

January 2003; 13 (1)

• Suspected hepatobiliary reactions to the newer antidepressants
• Convulsions and newer-generation antihistamines
• Drug Safety Information Workshop Report
• Case presentation: RespirActin
• Summary of advisories

October 2002; 12 (4)

• Natural Health Products: adverse reactions
• Leflunomide (Arava): hematologic, hepatic and respiratory reactions
• Case Presentation: moxifloxacin
• Summary of Advisories
• Drugs and grapefruit: interactions

July 2002; 12 (3)

• Pure red cell aplasia and Eprex
• Glitazones: update on adverse reactions
• Safety of human insulins
• Case presentation : Kava
• Summary of Advisories

April 2002; 12 (2)

• Marketed Health Products Directorate
• Selective COX-2 inhibitors
• Summary of advisories
• Oral sodium phosphates solutions
• Case presentation
• Adverse reaction reporting - 2001

January 2002; 12 (1)

• Statins: rhabdomyolysis and myopathy
• Alendronate: suspected pancreatitis
• HIV-associated lipodystrophy syndrome: overview and summary of case reports
• Summary of drug advisories
• Communiqué - Ibuprofen pediatric oral liquid: gastrointestinal bleeding

October 2001; 11(4)

• Antitubercular drugs: hepatobiliary reactions
• Electronic subscription to this Newsletter and drug advisories
• Health professional advisories
• Atypical antipsychotics: impaired glucose metabolism
• Communiqué - Brimonidine (Alphagan) ophthalmic drops: accidental ingestion

July 2001; 11(3)

• Drug advisories now available on the Web
• Miconazole-warfarin interaction: increased INR
• New toll-free numbers to report ADRs
• Rosiglitazone (Avandia): hepatic, cardiac and hematological reactions
• Adverse drug reaction reporting - 2000: Part 2
• Communiqué
  • Orlistat (Xenical) interaction with coumarin derivatives: increased INR
  • Azithromycin (Zithromax): myocardial infarction
  • Drugs of Current Interest

April 2001; 11(2)

• Adverse drug reaction reporting - 2000: Part 1
• Antiparkinsonian drugs and "sleep attacks"
• Rofecoxib (Vioxx): a year in review
• Communiqué - Warfarin and glucosamine: interaction
• Drugs of Current Interest

January 2001; 11(1)

• Thioridazine (Mellaril) and mesoridazine (Serentil): prolongation of the QTc interval
• Clopidogrel (Plavix): hematological reactions
• Gentamicin ear drops and ototoxicity: update
• Drugs of Current Interest

October 2000; 10(4)

• New influenza drugs: unexpected serious reactions
• Intravenous Rh_O [D] immune globulin [human]: suspected hemolytic/renal adverse reactions
• Abboject® Unit-of-Use Syringe: reports of malfunction
• Communiqué
  • Glucosamine sulfate: hyperglycemia
  • Ketotifen (Zaditen®): sleep apnea
  • Diclofenac (Voltaren Ophtha®) and ketorolac tromethamine (Acular®): corneal ulceration
• Drugs of Current Interest

July 2000; 10 (3)

• St. John's wort: harmful drug interaction
• Olanzapine (Zyprexa): suspected serious reactions
• Sildenafil (Viagra): cardiac risks
• New Bureau Name
• Communiqué
  • Citalopram (Celexa) and clarithromycin (Biaxin): interaction
  • Itraconazole (Sporanox): serum sickness-like disorder
• Drugs of Current Interest

April 2000; 10 (2)

• Adverse drug reaction reporting - 1999
• Celecoxib (Celebrex): 1 year later
• Correction - ticlopidine
• Communiqué - orlistat (Xenical): pancreatitis
• Drugs of Current Interest

January 2000; 10 (1)

• Cisapride (Prepulsid): interactions
• Pemoline (Cylert): market withdrawal
• Bupropion (Zyban): update
• Communiqué
  • HIV protease inhibitors: paronychia
  • Gingko biloba: bleeding disorders
• Drugs of Current Interest

October 1999;9(4)

• Serious hematologic reactions associated with ticlopidine - update
• Leukotriene receptor antagonists: suspected adverse reactions
• Communiqué - Ropinirole (Requip): sleep disorder

July 1999; 9(3)

• Alteplase (Activase rt-PA) for acute ischemic stroke
• Abciximab (ReoPro): risk of acute thrombocytopenia
• Nefazodone (Serzone) and hepatotoxicity
• Communiqué - Amlodipine (Norvasc): hearing loss

April 1999; 9(2)

• Bupropion (Zyban): suspected adverse reactions
• 1998 ADR Statistics
• Updates: immune globulin IV products, tolcapone (Tasmar)
• Communiqué - Olanzapine (Zyprexa): priapism

January 1999; 9(1)

• Isotretinoin and depression
• Low-dose ASA and GI Bleeding
• Guidelines for reporting ADRs
• Communiqué - azithromycin, pentoxifylline, sertraline and carbamazepine: interaction

October 1998; 8(4)

• Recent News About Drug Risks
• New Ontario Regional ADR Centre
• Discontinuation Reactions Associated With SSRIs
• Communiqué - amantadine and warfarin, pantoprazole

July 1998; 8(3)

• Quality Information in Spontaneous Reports
• Donepezil: Suspected Adverse Reactions
• Olanzapine: Hematological Reactions
• Communiqué - valproic acid, cefaclor, latanoprost, protease inhibitors

April 1998; 8(2)

• Alendronate-induced esophagitis
• 1997 ADR statistics
• Communiqué - dorzolamide hydrochloride, hydroxychloroquine sulfate, torvastatin calcium, risperidone, venlafaxine hydrochloride

January 1998; 8(1)

• Drugs: QT interval prolongation and torsades de pointes
• Ciprofloxacin use in epileptic patients taking phenytoin
• Appetite suppressants - update
• Communiqué - vigabatrin, mefloquine, lamotrigine

October 1997; 7(4)

• Calcium-channel blockers
• Azithromycin - severe iatrogenic hepatitis
• Newsletter survey results
• Communiqué - protease inhibitors, vigabatrin, terconazole, Fen-phen, heparin, paroxetine

July 1997; 7(3)

• ACE inhibitors and bronchospasm
• Interferon beta-1b
• Radiopharmaceuticals
• New Expert Advisory Committee on Pharmacovigilance

April 1997; 7(2)

• Adverse drug reaction reporting - 1996
• Potential abuse of butorphanol nasal spray
• Aminoglycoside ear drops and ototoxicity

January 1997; 7(1)

• Primary pulmonary hypertension and appetite suppressants
• HIV protease inhibitors and increased bleeding in hemophilia?
• Erythema multiforme and nifedipine
• Congenital anomalies and fluconazole

October 1996; 6(4)

• Cefaclor-associated serum sickness-like reaction
• Newsletter Assessment - Questionnaire

July 1996; 6(3)

• Cisapride: Arrhythmia Awareness
• Midazolam: A Wake-Up Call
• Clarithromycin: Tooth Discolouration and Smell Alteration

April 1996; 6(2)

• Metformin: Lactic Acidosis
• Nefazodone: ADR Profile
• 1995 Statistics ADR or Product Fault?

January 1996; 6(1)

• Cotrimoxazole
• Nicotine Patches and exercise
• Terbinafine - hepatobiliary reactions
• SSRIs - hyponatremia

October 1995; 5(4)

• Update: Fertility Drugs
• Propofol: Convulsions
• Contraindications: Dinoprostone
• Vaginal Gel
• DOCI List

July 1995; 5(3)

• Reporting Adverse Drug Reactions
• Lamotrigine (Lamictal): rashes
• Drug Names: confusion from two fronts
• Tiaprofenic Acid: cystitis
• Ticlopidine: revisited
• DOCI List

April 1995; 5(2)

• Zidovudine: Benefits of use during pregnancy
• Serevent®: Patient warnings must be stressed
• Fluoroquinolones: Tendonitis
• Topical Antifungals: Recent switch to over-the-counter
• Phenazopyridine: Hemolytic anemia

January 1995; 5(1)

• Risperidone and EPS Sumatriptan and migraine exacerbation
• Bromocriptine
• Fertility drug awareness
• New regional centre for Quebec

October 1994; 4(3)

• Regional Centres
• New Drugs - Serzone, Neurontin, Sabril
• Drugs of current interest

July 1994; 4(2)

• Editorial Note
• Terbinafine Herbal preparations

March 1994; 4(1)

• Rhabdomyolysis and HMG-CoA
• Reductase Inhibitors
• Antidepressants and Suicide
• Help Wanted: Risperdal

November 1993; 3(2)

• Ticlopidine HCl - Hematological and Liver Effects
• H1-Antihistamines - Cardiotoxic Effects

August 1993; 3(1)

• ACE Inhibitors: Renal Effects
• Sumatriptan Succinate: Chest Pain
• Nicotine Patches: Update / Inadvertent Exposure

April 1992; 2(1)

• ADR Program, 1991 Annual Report
• Case Report: Drug Interactions with Omeprazole
• Vasospasm with B-Blockers
• GI Bleeding with Toradol®

August 1991; 1(2)

• PPSP Workshop Minocycline - Case reports of severe liver and renal reactions
• ADRs in the Elderly Ciprofloxacin - ADR profile Diclofenac - Hepatic reactions

January 1991; 1(1)

• Saskatchewan ADR Pilot Project
• The WHO Connection Working Group on ADR Assessment